U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07012980) titled 'Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL' on May 24.
Brief Summary: This study aims to assess the efficacy and safety of the chemotherapy-light combination of glofitamab, polatuzumab vedotin and zanubrutinib (GPZ) in elderly patients with previously untreated diffuse large B-cell lymphoma.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Diffuse Large B-Cell Lymphoma
Intervention:
DRUG: Glofitamab
Glofitamab will be administered i.v. on a step-up dosing schedule starting on Day 8 of Cycle 1 (2.5 mg), Day 15 of Cycle 1 (10 mg), followed by 30 mg on Day 1 of Cycles 2-6, with ea...